We analyze, reanalyze and verify complex omics data—from data quality assessment and robust statistical modeling to biological interpretation, biomarker prioritization and validation-ready evidence.
Start with an Independent Omics Evidence Review. Move into biomarker validation strategy when the evidence is clear, or begin with expert-led analysis and reanalysis when the work must be built from the ground up.
A focused assessment of an existing dataset, report, manuscript or analysis plan to determine what is reliable, what needs correction and what should happen next.
Turn candidate signals into a defensible validation plan by prioritizing biomarkers that remain credible across methods, samples, subgroups and analytical assumptions.
End-to-end analysis or reanalysis of proteomics, metabolomics, glycomics and targeted LC-MS/MS data, with senior scientific oversight throughout the workflow.
Recent life-science literature highlights four unresolved needs that sit between computational output and a decision that can be trusted.
“AI cannot judge biological meaning or verify scientific validity.”npj Digital Medicine · Rethinking bioinformatics expertise
Expert-led study framing, robust statistical strategy and biological interpretation determine what the data actually support.
“We review the erosion of trust in AI outputs driven by poor reusability and reproducibility.”Nature Methods · Open and sustainable AI
Transparent preprocessing, documented assumptions, sensitivity analyses and reproducible workflows make evidence traceable and reviewable.
“The conditional safety estimates, low-reliability reference standard, and rater- and workload-dependent patterns do not support fully automated deployment.”npj Digital Medicine · Human-in-the-loop validation
Independent review and reanalysis challenge automated and conventional outputs and reveal hidden analytical risks.
“After addressing challenges in data, biological complexity, scalability and experimental validation, GBAI has the potential to deepen our understanding of disease pathways and biomarkers…”Nature Biotechnology · Generalist biological AI
Biomarker prioritization, validation criteria and study design connect computational signals with the next defensible experiment.
Selected statements are presented for scientific context. QuantiraOmics is not affiliated with or endorsed by the cited journals or publishers.
Two anonymized examples of how analytical risk is identified, tested, and converted into a defensible next decision.
Reviewed preprocessing, normalization, group modeling, effect sizes, and candidate stability for patient-derived metabolomics or proteomics data.
Built a simulation framework to test OLS and robust regression across outliers, sample sizes, and signal-strength scenarios.
QuantiraOmics is a Germany-based, expert-led consultancy for omics analysis, reanalysis and independent evidence verification—combining AI-enabled efficiency with robust biostatistics, LC-MS/MS domain expertise, biological interpretation and biomarker validation strategy.
Send the dataset type, scientific question, and current decision point. QuantiraOmics will identify the key analytical risks, define the evidence needed, and recommend the most useful next step.
